What is the Return on Assets (ROA) of RemeGen Co this year?
The Return on Assets (ROA) of RemeGen Co is -0.27 undefined this year.
RemeGen Co ROA 2024
RemeGen Co ROA
-0.27
Ticker
9995.HK
ISIN
CNE1000048G6
WKN
A2QGM4
In 2024, RemeGen Co's return on assets (ROA) was -0.27, a 64.79% increase from the -0.17 ROA in the previous year.
RemeGen Co Aktienanalyse
What does RemeGen Co do?
RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding RemeGen Co's Return on Assets (ROA)
RemeGen Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing RemeGen Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider RemeGen Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in RemeGen Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about RemeGen Co stock
What was the ROA of RemeGen Co compared to the previous year?
The ROA of RemeGen Co has increased by 64.79% compared to the previous year.
What consequences do high ROA have for investors of RemeGen Co?
A high ROA is advantageous for investors of RemeGen Co, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in RemeGen Co?
A low ROA can be unfavorable for investors of RemeGen Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of RemeGen Co affect the company?
An increase in ROA of RemeGen Co can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of RemeGen Co impact the company?
A reduction in the ROA of RemeGen Co can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of RemeGen Co?
Some factors that can influence the ROA of RemeGen Co include revenue, operating costs, asset structure, and industry average.
Why is the ROA of RemeGen Co important for investors?
The ROA of RemeGen Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can RemeGen Co take to improve ROA?
To improve ROA, RemeGen Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does RemeGen Co pay?
Over the past 12 months, RemeGen Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RemeGen Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of RemeGen Co?
The current dividend yield of RemeGen Co is .
When does RemeGen Co pay dividends?
RemeGen Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of RemeGen Co?
RemeGen Co paid dividends every year for the past 0 years.
What is the dividend of RemeGen Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is RemeGen Co located?
RemeGen Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von RemeGen Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of RemeGen Co from 9/18/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did RemeGen Co pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of RemeGen Co in the year 2023?
In the year 2023, RemeGen Co distributed 0 CNY as dividends.
In which currency does RemeGen Co pay out the dividend?
The dividends of RemeGen Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von RemeGen Co
Our stock analysis for RemeGen Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
